Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes

NCT05478707 · Suspended

Last updated 2026-05-28

This clinical trial tests different treatment approaches to improve blood vessel function in adults with type 1 diabetes who have microvascular dysfunction.

Status Suspended Paused for now; may resume later.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, triple-blind basic-science study

Participants 47 people Planned (estimated).

Who can join Ages 18–40 · all sexes

Timeline Started 2023-10 · est. completion 2028-07

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT05478707 ↗

Description as written by the study sponsor.

The investigators will test the hypothesis that, in adults with type 1 diabetes (T1D), glucagon-like peptide-1 receptor agonism (GLP-1RA, i.e. dulaglutide) enhances insulin-mediated skeletal muscle microvascular perfusion via attenuating endothelial oxidative stress and thereby improving endothelial function.

Treatments tested

Dulaglutide Drug

GLP1-RA
Placebo Drug

Saline placebo

Main thing measured	Microvascular blood volume (MBV)
Sponsor	University of Virginia
Conditions studied	Diabetes Mellitus, Type 1, Endothelial Dysfunction
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05478707 ↗